We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Eterna Therapeutics Inc (ERNA) USD0.005

Sell:$1.10 Buy:$1.18 Change: $0.17 (13.39%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.10
Buy:$1.18
Change: $0.17 (13.39%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.10
Buy:$1.18
Change: $0.17 (13.39%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Contact details

Address:
1035 Cambridge Street, Suite 18A
CAMBRIDGE
02141
United States
Telephone:
+1 (212) 5821199
Website:
https://eternatx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ERNA
ISIN:
US1140822099
Market cap:
$5.62 million
Shares in issue:
5.41 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • James Bristol
    Chairman of the Board
  • Sanjeev Luther
    President, Chief Executive Officer
  • Sandra Gurrola
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.